JaacksLMVandevijvereSPanA, et al.The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol2019; 7(3): 231–240.
2.
Global BMI Mortality CollaborationDi AngelantonioEBhupathirajuSNet al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016; 388(10046): 776–786.
3.
AbdelaalMle RouxCWDochertyNG. Morbidity and mortality associated with obesity. Ann Transl Med2017; 5(7): 161.
4.
MarlattKLPitynski-MillerDRGavinKM, et al.Body composition and cardiometabolic health across the menopause transition. Obesity2022; 30(1): 14–27.
5.
RubinoFCummingsDEEckelRH, et al.Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol2025; 13: 221–262.
6.
Lopez-JimenezFAlmahmeedWBaysH, et al.Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022; 29(17): 2218–2237.
7.
StefanNSchulzeMB. Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment. Lancet Diabetes Endocrinol2023; 11(6): 426–440.
8.
CrosbieEJKitsonSJMcAlpineJN, et al.Endometrial cancer. Lancet2022; 399(10333): 1412–1428.
9.
BarrCERyanNAJDerbyshireAE, et al.Weight loss during intrauterine progestin treatment for obesity-associated atypical hyperplasia and early-stage cancer of the endometrium. Cancer Prev Res2021; 14(11): 1041–1050.
10.
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023; 402(10397): 203–234.
11.
International Diabetes Federation. Diabetes is “a pandemic of unprecedented magnitude” now affecting one in 10 adults worldwide. Diabetes Res Clin Pract2021; 181: 109133. DOI: 10.1016/j.diabres.2021.109133.
12.
HuXWangYYangK, et al.Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews. Endocrine2025; 16: 04179.
13.
JastreboffAMle RouxCWStefanskiA, et al.Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med2024; 392: 958–971.
14.
KaragiannisTMalandrisKAvgerinosI, et al.Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia2024; 67(7): 1206–1222.
15.
DeanfieldJVermaSSciricaBM, et al.Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet2024; 404(10454): 773–786.
16.
PackerMZileMRKramerCM, et al.Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med2025; 392(5): 427–437. DOI: 10.1056/NEJMoa2410027.
17.
SyedAAAdamSMillerCA, et al.Obesity management for patients with coronary artery disease and heart failure. Heart Fail Clin2025; 21: 257–271.
18.
National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity. London: NICE, 2023. https://www.nice.org.uk/guidance/ta875.
19.
National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity. London: NICE, 2024. https://www.nice.org.uk/guidance/ta1026.
20.
RovinskiDRamosRBFigheraTM, et al.Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res2018; 168: 83–95.
21.
MukherjeeADavisSR. Update on menopause hormone therapy; current indications and unanswered questions. Clin Endocrinol (Oxf)2025. DOI:10.1111/cen.15211.
KapitzaCNosekLJensenL, et al.Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol2015; 55(5): 497–504.
24.
JordyABBreitschaftAChristiansenE, et al.Oral semaglutide does not affect the bioavailability of the combined oral contraceptive ethinylestradiol/levonorgestrel. Diabetes2018; 67(Supplement_1): 1135.
EttingerBLiDKKleinR. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril1998; 69(5): 865–869.
28.
ManleyKHillardTClarkJet al. Management of unscheduled bleeding on HRT: a joint guideline on behalf of the British Menopause Society, Royal College Obstetricians and Gynaecologists, British Gynaecological Cancer Society, British Society for Gynaecological Endoscopy, Faculty of Sexual and Reproductive Health, Royal College of General Practitioners and Getting it Right First Time. Post Reprod Health2024; 30(2): 95–116. DOI: 10.1177/20533691241254413.
